Comment from Padagis
AnonymousSupportBusiness
Summary: Padagis US LLC supports the continued use of the SUPAC guidances while requesting specific updates to improve clarity, modernize the risk-based approach, and expand coverage to include more dosage forms. They suggest aligning the guidances with ICH Q9 and Q12 principles and providing more specific examples for change levels.
See attached file(s)